GrandPharma of China has licensed  China  rights to Acetium capsules from Biohit Oyj, a Finish pharmaceutical company. Acetium reduces the level of acetaldehyde, a carcinogen, in the GI tract. GrandPharma will manufacture and distribute the product in  China , once SFDA approval has been granted, a process that will take about two years. The agreement includes a diagnostic kit that tests for excessive acetaldehyde. Financial details were not disclosed. More details.... Stock Symbol: (HK: 512) Share this with colleagues: // //